Startseite>>Signaling Pathways>> Neuroscience>> COX>>Mefenamic Acid

Mefenamic Acid (Synonyms: C.I. 473, CN 35355, NSC 94437)

Katalog-Nr.GC11096

MefenaminsÄure ist ein nichtsteroidaler EntzÜndungshemmer, der als kompetitiver Inhibitor von hCOX-1 und hCOX-2 wirkt, mit IC50-Werten von 40 nM und 3 μM fÜr hCOX-1 bzw. hCOX-2.

Products are for research use only. Not for human use. We do not sell to patients.

Mefenamic Acid Chemische Struktur

Cas No.: 61-68-7

Größe Preis Lagerbestand Menge
10mM (in 1mL DMSO)
35,00 $
Auf Lager
50mg
50,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Mefenamic acid is a non-steroidal anti-inflammatory agent, acting as a competitive inhibitor of hCOX-1 and hCOX-2, with IC50s of 40 nM and 3 μM for hCOX-1 and hCOX-2, respectively.

Mefenamic acid is a non-steroidal anti-inflammatory agent, acting as a competitive inhibitor of hCOX-1, with IC50s of 40 nM and 3 μM for hCOX-1 and hCOX-2, respectively[1]. Mefenamic acid (0-100 μM) has cytotoxic effects on KB, Saos-2, and 1321N cells, however, U-87MG cells are resistant to Mefenamic acid[2].

References:
[1]. Gierse JK, et al. Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase. Biochem J. 1995 Jan 15;305 (Pt 2):479-84.
[2]. Hashemipour MA, et al. In Vitro Cytotoxic Effects of Celecoxib, Mefenamic Acid, Aspirin and Indometacin on Several Cells Lines. J Dent (Shiraz). 2016 Sep;17(3):219-25.

Bewertungen

Review for Mefenamic Acid

Average Rating: 5 ★★★★★ (Based on Reviews and 36 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Mefenamic Acid

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.